<DOC>
	<DOCNO>NCT00196599</DOCNO>
	<brief_summary>In 1999 , initiate antiretroviral treatment HIV infect adult , triple combination protease inhibitor recommend . Such therapy induces side effect number pill may reduce therapy adherence . The aim study evaluate efficacy safety daily FTC , ddI , efavirenz combination , HIV patient CD4 cell count 100/mm3 , antiretroviral naive .</brief_summary>
	<brief_title>Pilot Study Once Daily FTC , ddI , Efavirenz Combination Antiretroviral Naive HIV Infected Adults</brief_title>
	<detailed_description>In 1999 , initiate antiretroviral treatment HIV infect adult , triple combination protease inhibitor recommend . Side effect product number pill may induce low adherence , thus low efficacy . 40 patient CD4 count 100/mm3 , HIV RNA 5,000 copies/ml antiretroviral naive , take daily combination FTC , ddI , efavirenz 24 week . The primary end-point viral success maintain 12 week 24 week . Secondary end-point adherence association safety . The trial prolong total 72 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>HIV infection Antiretroviral naive CD4 cell count 100/mm3 Plasma HIV RNA load 5,000 copies/mL Signed write informed consent Hepatitis B infection Pregnancy Alcool abuse Acute infection , past neurological pancreatic disease , biological abnormality Chemotherapy immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>